Clinical Trial Update: A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 study evaluating XL-820 in adults with advanced gastrointestinal stromal tumors resistant to imatinib and/or s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• XL-820

Snippet

Sponsor: Exelixis | Conditions: Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms | Phase 2 | Status: COMPLETED